natgillin/translations-raw huggingface dataset:
The product therefore does not fulfil the requirement of Additional Note 1 to Chapter 30, last paragraph, and cannot be classified under heading 3004 (see also the Combined Nomenclature Explanatory Notes (CN EN) to Chapter 30, Additional Note 1, point 3).
Proizvod zato ne izpolnjuje zahtev iz zadnjega odstavka dodatne opombe 1 k poglavju 30 in ga ni mogoče uvrstiti pod tarifno številko 3004 (glej tudi pojasnjevalne opombe h kombinirani nomenklaturi (PO KN), točka 3 dodatne opombe 1 k poglavju 30).
Given its characteristics the product is therefore to be classified as a food preparation of heading 2106.
Glede na lastnosti se proizvod zato uvrsti kot živilski pripravek pod tarifno številko 2106.
Commission Regulation (EU) No 381/2010
Uredba Komisije (EU) št. 381/2010
This Regulation shall enter into force on 5 May 2010.
Ta uredba začne veljati 5. maja 2010.
Commission Regulation (EU) No 382/2010
Uredba Komisije (EU) št. 382/2010
of 5 May 2010
z dne 5. maja 2010
refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health
o zavrnitvi odobritve nekaterih zdravstvenih trditev na živilih, razen tistih, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok
The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as the Authority.
Nacionalni pristojni organ veljavne vloge pošlje Evropski agenciji za varnost hrane (v nadaljnjem besedilu: Agencija).
Following an application from The Natural Push-Up Company, submitted on 28 November 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Natural Push-Up® Tablets and Natural Push-Up® Capsules on female breast enhancement (Question No EFSA-Q-2008-784) [2].
Družba The Natural Push-Up je 28. novembra 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki tablet Natural Push-Up® in kapsul Natural Push-Up® na povečanje ženskih prsi (Vprašanje št. EFSA-Q-2008-784) [2].
The claim proposed by the applicant was worded as follows: ‘NPU Tablets imitate female breasts enhancement process by 8-PN (8-Prenylnaringenin)’.
Vlagatelj je predlagal naslednjo trditev: „Tablete NPU s pomočjo 8-PN (8-prenilnaringenina) posnemajo proces povečanja ženskih prsi“.
On 5 June 2009, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Natural Push-Up® Tablets and Natural Push-Up® Capsules and the claimed effect.
Komisija in države članice so 5. junija 2009 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem tablet Natural Push-Up® in kapsul Natural Push-Up® ter navedeno trditvijo ni utemeljena.
Following an application from Clasado Ltd., submitted on 29 December 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of BimunoBT (BGOS) Prebiotic on maintaining a healthy gastro-intestinal function (Question No EFSA-Q-2009-00231) [3].
Družba Clasado Ltd. je 29. decembra 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki prebiotika BimunoBT (BGOS) na vzdrževanje zdravega delovanja prebave (Vprašanje št. EFSA-Q-2009-00231) [3].
The claim proposed by the applicant was worded as follows: ‘Helps maintain a healthy gastro-intestinal (GI) function’.
Vlagatelj je predlagal naslednjo trditev: „Pomaga vzdrževati zdravo delovanje prebave“.
On 7 July 2009, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of BimunoBT (BGOS) Prebiotic and the claimed effect.
Komisija in države članice so 7. julija 2009 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem prebiotika BimunoBT (BGOS) in navedeno trditvijo ni utemeljena.
Following an application from Clasado Ltd., submitted on 15 July 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of BimunoBT (BGOS) Prebiotic on support of the immune system (Question No EFSA-Q-2009-00230) [4].
Družba Clasado Ltd. je 15. julija 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki prebiotika BimunoBT (BGOS) na krepitev imunskega sistema (Vprašanje št. EFSA-Q-2009-00230) [4].
The claim proposed by the applicant was worded as follows: ‘Supports your natural defences’.
Vlagatelj je predlagal naslednjo trditev: „Krepi vašo naravno odpornost“.
On 7 July 2009, the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of BimunoBT (BGOS) Prebiotic and the claimed effect.
Komisija in države članice so 7. julija 2009 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem prebiotika BimunoBT (BGOS) in navedeno trditvijo ni utemeljena.
Following an application from Sunstar Suisse S.A., submitted on 4 February 2009 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Gum PeriobalanceTM tablets and chewing gum on oral health (Question No EFSA-Q-2009-00373) [5].
Družba Sunstar Suisse S.A. je 4. februarja 2009 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki tablet in žvečilnih gumijev Gum PeriobalanceTM na zdravje ustne votline (Vprašanje št. EFSA-Q-2009-00373) [5].
The claim proposed by the applicant was worded as follows: ‘Gum PeriobalanceTM, combined with a correct oral hygiene, helps re-balancing the oral microflora and improving oral health’.
Vlagatelj je predlagal naslednjo trditev: „Izdelki Gum PeriobalanceTM ob redni skrbi za ustno higieno pomagajo uravnovesiti ustno mikrofloro in izboljšati zdravje ustne votline.“
On 20 July 2009, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Gum PeriobalanceTM tablets and chewing gum and the claimed effect.
Komisija in države članice so 20. julija 2009 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem tablet in žvečilnih gumijev Gum PeriobalanceTM ter navedeno trditvijo ni utemeljena.
Health claims referred to in Article 13(1)(a) of Regulation (EC) No 1924/2006 are subject to the transition measures laid down in Article 28(5) of that Regulation only if they comply with the conditions therein mentioned, among which that they have to comply with the Regulation.
Zdravstvene trditve iz člena 13(1)(a) Uredbe (ES) št. 1924/2006 so predmet prehodnega ukrepa iz člena 28(5) navedene uredbe, samo če izpolnjujejo navedene pogoje, med katerimi je ta, da so v skladu z Uredbo.
As for the four claims subject to the present Regulation, the Authority concluded that a cause and effect relationship had not been established between the consumption of the foods and the claimed effects and thus they do not comply with the Regulation (EC) No 1924/2006, they could not benefit from the transition period foreseen in Article 28(5) of that Regulation.
Ker je Agencija ugotovila, da v primeru štirih trditev, ki so predmet te uredbe, vzročno-posledična povezava med uživanjem živil in navedenimi trditvami ni utemeljena ter zato niso v skladu z Uredbo (ES) št. 1924/2006, se prehodno obdobje iz člena 28(5) navedene uredbe ne more uporabiti.
A transition period of six months is provided for to enable food business operators to adapt to the requirements laid down in this Regulation.
Določeno je šestmesečno prehodno obdobje, da se nosilci živilske dejavnosti lahko prilagodijo zahtevam iz te uredbe.
Done at Brussels, 5 May 2010.
V Bruslju, 5. maja 2010
The EFSA Journal (2009) 1100, 1-9.
The EFSA Journal (2009) 1100, str. 1–9.
The EFSA Journal (2009) 1107, 1-10.
The EFSA Journal (2009) 1107, str. 1–10.
The EFSA Journal (2009) 1106, 1-8.
The EFSA Journal (2009) 1106, str. 1–8.
The EFSA Journal (2009) 1178, 1-8.
The EFSA Journal (2009) 1178, str. 1–8.
Natural Push-Up® Tablets and Natural Push-Up® Capsules
tablete Natural Push-Up® in kapsule Natural Push-Up®
NPU Tablets imitate female breasts enhancement process by 8-PN (8-Prenylnaringenin)
Tablete NPU s pomočjo 8-PN (8-prenilnaringenina) posnemajo proces povečanja ženskih prsi.
Helps maintain a healthy gastro-intestinal (GI) function
Pomaga vzdrževati zdravo delovanje prebave.
Supports your natural defences
Krepi vašo naravno odpornost.
Gum PeriobalanceTM tablets and chewing gum
tablete in žvečilni gumiji Gum PeriobalanceTM
Gum PeriobalanceTM, combined with a correct oral hygiene, helps re-balancing the oral microflora and improving oral health
Izdelki Gum PeriobalanceTM ob redni skrbi za ustno higieno pomagajo uravnovesiti ustno mikrofloro in izboljšati zdravje ustne votline.
BimunoBT (BGOS) Prebiotic
prebiotik BimunoBT (BGOS)
Commission Regulation (EU) No 383/2010
Uredba Komisije (EU) št. 383/2010
Following an application from ELVIR S.A.S., submitted on 5 June 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a milk product, rich in fibre and protein, on the reduction of the sense of hunger (Question No EFSA-Q-2008-396) [2].
Družba ELVIR S.A.S. je 5. junija 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki mlečnega izdelka, bogatega z vlakninami in beljakovinami, na zmanjševanje občutka lakote (vprašanje št. EFSA-Q-2008-396) [2].
The claim proposed by the applicant was worded as follows: ‘This product reduces the sense of hunger’.
Vlagatelj je predlagal naslednjo trditev: „Ta proizvod zmanjšuje občutek lakote“.
On 19 December 2008, the Commission and the Member States received the scientific opinion from the Authority.
Komisija in države članice so 19. decembra 2008 prejele znanstveno mnenje Agencije.
It followed from the opinion and subsequent clarification from the Authority that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of the milk product, rich in fibre and protein, and a reduction of the sense of hunger that is nutritionally or physiologically beneficial in terms of effect on food energy intake.
Iz mnenja in naknadnega pojasnila je razvidno, da je Agencija na podlagi predloženih podatkov ugotovila, da vzorčno-posledična povezava med uživanjem mlečnega izdelka, bogatega z vlakninami in beljakovinami, in zmanjševanjem občutka lakote, ki je prehransko in fiziološko koristen v smislu učinka na energijski vnos, ni utemeljena.
Considering this, the Standing Committee of the Food Chain and Animal Health, at its meeting of 27 April 2009 concluded that the health claim should be subject to further consideration and the Commission submitted on 24 June 2009 a request to the Authority for further advice on a number of elements in relation to the submitted application.
Stalni odbor za prehranjevalno verigo in zdravje živali je na srečanju 27. aprila 2009 sklenil, da je potrebna nadaljnja preučitev zdravstvene trditve, Komisija pa je 24. junija 2009 Agenciji predložila zahtevo za nadaljnje svetovanje o številnih elementih v zvezi s predloženo vlogo.
On 22 July 2009 the Commission and the Member States received the response from the Authority where it is clarified that the effect observed could not be attributed solely to the food tested because of the lack of information on the dietary conditions of the studies.
Komisija in države članice so 22. julija 2009 prejele odgovor Agencije s pojasnilom, da se obravnavanega učinka ne more pripisati izključno testiranemu živilu zaradi pomanjkljivih informacij o prehranskih pogojih študij.
Accordingly, that health claim can not be considered as complying with the requirements of Regulation (EC) No 1924/2006, and it should not be authorised.
Ker se šteje, da zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne sme odobriti.
The comments from the applicants and the members of the public received by the Commission, pursuant to Article 16(6) of Regulation (EC) No 1924/2006, have been considered when setting the measures provided for in this Regulation.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vložniki in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
The EFSA Journal (2008) 894, 1-9.
The EFSA Journal (2008) 894, str. 1–9.
Rejected health claim
Zavrnjena zdravstvena trditev
Application — relevant provisions of Regulation (EC) No 1924/2006
Vloga – ustrezne določbe Uredbe (ES) št. 1924/2006
Milk product, rich in fibre and protein
Mlečni izdelek, bogat z vlakninami in beljakovinami
This product reduces the sense of hunger
Ta proizvod zmanjšuje občutek lakote.
Health claims referred to in Article 13(1)(c) of Regulation (EC) No 1924/2006 are subject to the transition measures laid down in Article 28(6) of that Regulation only if they comply with the conditions therein mentioned, among which that the applications for health claims not subject of evaluation and authorisation in a Member State have to be made before 19 January 2008.
Zdravstvene trditve iz člena 13(1)(c) Uredbe (ES) št. 1924/2006 so predmet prehodnih ukrepov iz člena 28(6) navedene uredbe le, če izpolnjujejo pogoje, navedene v tej uredbi, med katerimi je ta, da se vloge za zdravstvene trditve, ki niso predmet ocenjevanja in odobritve v državi članici, sestavijo pred 19. januarjem 2008.
As the application for the health claim subject to the present Regulation was not made before that date it can not benefit from the transition period foreseen in Article 28(6) of that Regulation.
Ker vloga za zdravstveno trditev, ki je predmet te uredbe, ni bila sestavljena pred navedenim datumom, se prehodno obdobje iz člena 28(6) navedene uredbe ne uporablja.
Commission Regulation (EU) No 384/2010
Uredba Komisije (EU) št. 384/2010
on the authorisation and refusal of authorisation of certain health claims made on foods and referring to the reduction of disease risk and to children’s development and health
o odobritvi in zavrnitvi odobritve zdravstvenih trditev na živilih, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok
All the opinions referred to in this Regulation are related to applications for reduction of disease risk claims, as referred to in Article 14(1)(a) of Regulation (EC) No 1924/2006.
Vsa mnenja, navedena v tej uredbi, se nanašajo na vloge za zdravstvene trditve za zmanjšanje tveganja za nastanek bolezni, kot je določeno v členu 14(1)(a) Uredbe št. 1924/2006.
Following an application from Danone France, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Danacol® on blood cholesterol (Question No EFSA-Q-2008-779) [2].
Družba Danone France je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Danacol® na holesterol v krvi (vprašanje št. EFSA-Q-2008-779) [2].
The claim proposed by the applicant was worded as follows: ‘Danacol® reduces LDL-cholesterol by 10 % in 3 weeks, and the reduction is maintained with daily consumption.
Vlagatelj je predlagal naslednjo trditev: „Danacol® v 3 tednih zniža LDL-holesterol za 10 %, znižani holesterol pa se vzdržuje z dnevnim uživanjem.
High blood cholesterol is one of the main risk factors in the development of (coronary) heart disease’.
Povišan holesterol v krvi je eden glavnih dejavnikov tveganja za razvoj (koronarne) bolezni srca.“
On the basis of the data presented, the Authority concluded in its opinion received by the Commission on 3 August 2009 that a cause and effect relationship had been established between the daily consumption of 1,6 g of phytosterols and the claimed effect.
Agencija je v svojem mnenju, ki ga je Komisija prejela 3. avgusta 2009, na podlagi predloženih podatkov sklenila, da je vzročno-posledična povezava med dnevnim uživanjem 1,6 g rastlinskih sterolov in navedeno trditvijo bila utemeljena.
Accordingly, a health claim reflecting this conclusion should be considered as complying with the requirements of Regulation (EC) No 1924/2006, and it should be included in the Community list of permitted claims.
Zdravstveno trditev, ki odraža ta sklep, je zato treba šteti za skladno z zahtevami iz Uredbe (ES) št. 1924/2006 ter jo uvrstiti na seznam dovoljenih trditev Skupnosti.
On 3 August 2009, the Commission and the Member States received also the scientific opinion from the Authority, based on the request of the Commission and a similar request from France, following the conclusions of the Standing Committee of the Food Chain and Animal Health and in accordance with Article 19(2) of Regulation (EC) No 1924/2006, regarding the possibility to indicate a quantitative effect in health claims related to the effects of plant sterols/plant stanols esters and lowering of blood cholesterol (Question No EFSA-Q-2009-00530 and Q-2009-00718) [3].
Komisija in države članice so 3. avgusta 2009 prav tako prejele znanstveno mnenje Agencije o možnosti navedbe kvantitativnega učinka v zdravstvenih trditvah v zvezi z učinki rastlinskih sterolov/estrov rastlinskih stanolov in znižanjem holesterola v krvi (vprašanji št. EFSA-Q-2009-00530 in Q-2009-00718) [3], in sicer na podlagi zahteve Komisije in podobne zahteve Francije ter sklepov Stalnega odbora za prehranjevalno verigo in zdravje živali in v skladu s členom 19(2) Uredbe (ES) št. 1924/2006.
The Authority concluded that for a daily intake of 1,5-2,4 g plant sterols/stanols added to foods such as yellow fat spreads, dairy products, mayonnaise and salad dressings an average reduction of between 7 and 10,5 % can be expected and that such reduction is of biological significance.
Agencija je sklenila, da se pri dnevnem vnosu 1,5–2,4 g rastlinskih sterolov/stanolov, dodanih živilom, kot so rumene mazave maščobe, mlečni izdelki, majoneza in solatni prelivi, lahko pričakuje povprečno znižanje med 7 in 10,5 % ter da je tako znižanje biološko pomembno.
Accordingly, taking into account the scientific opinion from the Authority and in order to ensure that such health claims referring to the magnitude of the claimed effect are authorised in a way that would not mislead the consumer, and that their conditions of use are set in a coherent way, it is necessary to set different conditions of use than those proposed by the applicant.
Ob upoštevanju znanstvenega mnenja Agencije in za zagotovitev, da take zdravstvene trditve, ki se nanašajo na stopnjo učinka navedene trditve, ne zavajajo potrošnika ter da so njihovi pogoji uporabe usklajeni, je treba določiti drugačne pogoje uporabe, kot jih je predlagal vlagatelj.
Article 16(4) of Regulation (EC) No 1924/2006 provides that an opinion in favour of authorising a health claim should include certain particulars.
Člen 16(4) Uredbe (ES) št. 1924/2006 določa, da mora mnenje, ki podpira odobritev znanstvene trditve, vključevati nekatere podatke.
Accordingly, those particulars should be set out in the Annex I to the present Regulation as regards the authorised claim and include, as the case may be, the revised wording of the claim, specific conditions of use of the claim, and, where applicable, conditions or restrictions of use of the food and/or an additional statement or warning, in accordance with the rules laid down in Regulation (EC) No 1924/2006 and in line with the opinions of the Authority.
Navedene podatke v zvezi z odobreno trditvijo je zato treba določiti v Prilogi I k tej uredbi ter vanje vključiti, odvisno od primera, spremenjeno besedilo trditve, posebne pogoje uporabe trditve in, kadar je to ustrezno, pogoje ali omejitve uporabe živila in/ali dodatno pojasnilo ali opozorilo v skladu s pravili iz Uredbe (ES) št. 1924/2006 in mnenji Agencije.
One of the objectives of Regulation (EC) No 1924/2006 is to ensure that health claims are truthful, clear and reliable and useful to the consumer, and that wording and presentation are taken into account in that respect.
Eden od ciljev Uredbe (ES) št. 1924/2006 je zagotoviti, da je zdravstvena trditev resnična, jasna, zanesljiva in za potrošnika uporabna ter da se pri tem upoštevata besedilo in predstavitev trditve.
Therefore, where the wording of claims has the same meaning for consumers as that of an authorised health claim, because they demonstrate the same relationship that exists between a food category, a food or one of its constituents and health, they should be subject to the same conditions of use, as indicated in Annex I.
Kadar ima besedilo trditev za potrošnike enak pomen kot odobrena zdravstvena trditev, ker predstavljata isto povezavo med kategorijo živila, živilom ali njegovo sestavino in zdravjem, je treba te trditve uporabljati pod istimi pogoji, kot so navedeni v Prilogi I.
Following an application from Cambridge Theranostics Ltd., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lycopene-whey complex on risk of atherosclerotic plaques (Question No EFSA-Q-2008-703) [4].
Družba Cambridge Theranostics Ltd. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi kompleksa likopena in sirotke na tveganje aterosklerotičnih plakov (vprašanje št. EFSA-Q-2008-703) [4].
The claim proposed by the applicant was worded as follows: ‘Lycopene-whey complex prevents oxidative damage of plasma lipoproteins, which reduces the build up of arterial plaques and reduces the risk of heart disease, stroke and other clinical complications of atherosclerosis’.
Vlagatelj je predlagal naslednjo trditev: „Kompleks likopena in sirotke preprečuje oksidativne poškodbe plazemskih lipoproteinov, kar zmanjšuje nastajanje plakov v arterijah in tveganje za bolezni srca, kapi in drugih kliničnih zapletov ateroskleroze.“
On the basis of the data presented, the Authority concluded in its opinion received by the Commission on 3 August 2009 that a cause and effect relationship had not been established between the intake of Lycopene-whey complex and the claimed effect.
Agencija je v svojem mnenju, ki ga je Komisija prejela 3. avgusta 2009, na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med vnosom kompleksa likopena in sirotke in navedeno trditvijo ni bila utemeljena.
Following an application from Clasado Ltd., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of BimunoTM (BGOS) Prebiotic on reduction of the bad bacteria that can cause travellers’ diarrhoea (Question No EFSA-Q-2008-232) [5].
Družba Clasado Ltd. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi prebiotika BimunoTM (BGOS) na zmanjšanje slabih bakterij, ki lahko povzročijo potovalno drisko (vprašanje št. EFSA-Q-2008-232) [5].